よむ、つかう、まなぶ。
【参考資料4】抗微生物薬適正使用の手引き 第三版 本編 (132 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
78. Yahav D et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative
Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis. 2019
Sep;69(7):1091-1098.
79. Dach VE. et al. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day
Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With
Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. JAMA. 2020
Jun;323(21):2160-2169.
80. Molina J. et al. Seven-versus 14-day course of antibiotics for the treatment of bloodstream
infections by Enterobacterales: a randomized, controlled trial. Clin Microbiol Infect. 2022
Apr;28(4):550-557.
81. Turjeman A. et al. Duration of antibiotic treatment for Gram-negative bacteremia –
Systematic review and individual participant data (IPD) meta-analysis. EClinicalMedicine.
2022 Dec;55:101750.
82. Heil LE, et al. Optimizing the Management of Uncomplicated Gram-Negative Bloodstream
Infections: Consensus Guidance Using a Modified Delphi Process. Open Forum Infect Dis.
2021 Oct;8(10):ofab434.
83. Japanese Respiratory Society. Strategies for non-responders. Respirology. 2009 Nov;14
Suppl 2:S41-3.
84. Macfarlane JT. et al. Comparative radiographic features of community acquired Legionnaires'
disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax. 1984
Jan;39(1):28-33.
85. Pappas PG. et al. Invasive candidiasis. Nat Rev Dis Primers. 2018 May;4:18026.
86. Ioanas M. et al. Causes and predictors of nonresponse to treatment of intensive care unitacquired pneumonia. Crit Care Med. 2004 Apr;32(4):938-945.
87. Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA. 2016 Jul;316(3):325-337.
88. Nathwani D, Lawson W, Dryden M. et al, Implementing criteria-based early switch/early
discharge programmes: a European perspective. Clin Microbiol Infect. 2015 Sep; 21 Suppl 2:
S47-55.
89. ANTIMICROBIAL STEWARDSHIP FROM PRINCIPLES TO PRACTICE 2018 British Society
for Antimicrobial Chemotherapy
90. 野本英俊,忽那賢志,早川佳代子,大曲貴夫, 国立国際医療研究センター病院総合感染症科・国
際感染症センター. 経口抗菌薬へのスイッチを再考する. KANSEN Journal No.73
（2019.7.29）
91. Sevinç F. et al. Early switch from intravenous to oral antibiotics: guidelines and
implementation in a large teaching hospital. J Antimicrob Chemother. 1999 Apr;43(4):601606.
92. Cyriac JM, James E, Switch over from intravenous to oral therapy: A concise overview. J
Pharmacol Pharmacother. 2014 Apr; 5(2): 83-87.
93. 抗菌薬適正使用生涯教育テキスト 第 3 版
94. 日本化学療法学会 抗菌薬 TDM 臨床実践ガイドライン 2022
132
第三版
78. Yahav D et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative
Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis. 2019
Sep;69(7):1091-1098.
79. Dach VE. et al. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day
Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With
Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. JAMA. 2020
Jun;323(21):2160-2169.
80. Molina J. et al. Seven-versus 14-day course of antibiotics for the treatment of bloodstream
infections by Enterobacterales: a randomized, controlled trial. Clin Microbiol Infect. 2022
Apr;28(4):550-557.
81. Turjeman A. et al. Duration of antibiotic treatment for Gram-negative bacteremia –
Systematic review and individual participant data (IPD) meta-analysis. EClinicalMedicine.
2022 Dec;55:101750.
82. Heil LE, et al. Optimizing the Management of Uncomplicated Gram-Negative Bloodstream
Infections: Consensus Guidance Using a Modified Delphi Process. Open Forum Infect Dis.
2021 Oct;8(10):ofab434.
83. Japanese Respiratory Society. Strategies for non-responders. Respirology. 2009 Nov;14
Suppl 2:S41-3.
84. Macfarlane JT. et al. Comparative radiographic features of community acquired Legionnaires'
disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax. 1984
Jan;39(1):28-33.
85. Pappas PG. et al. Invasive candidiasis. Nat Rev Dis Primers. 2018 May;4:18026.
86. Ioanas M. et al. Causes and predictors of nonresponse to treatment of intensive care unitacquired pneumonia. Crit Care Med. 2004 Apr;32(4):938-945.
87. Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA. 2016 Jul;316(3):325-337.
88. Nathwani D, Lawson W, Dryden M. et al, Implementing criteria-based early switch/early
discharge programmes: a European perspective. Clin Microbiol Infect. 2015 Sep; 21 Suppl 2:
S47-55.
89. ANTIMICROBIAL STEWARDSHIP FROM PRINCIPLES TO PRACTICE 2018 British Society
for Antimicrobial Chemotherapy
90. 野本英俊,忽那賢志,早川佳代子,大曲貴夫, 国立国際医療研究センター病院総合感染症科・国
際感染症センター. 経口抗菌薬へのスイッチを再考する. KANSEN Journal No.73
（2019.7.29）
91. Sevinç F. et al. Early switch from intravenous to oral antibiotics: guidelines and
implementation in a large teaching hospital. J Antimicrob Chemother. 1999 Apr;43(4):601606.
92. Cyriac JM, James E, Switch over from intravenous to oral therapy: A concise overview. J
Pharmacol Pharmacother. 2014 Apr; 5(2): 83-87.
93. 抗菌薬適正使用生涯教育テキスト 第 3 版
94. 日本化学療法学会 抗菌薬 TDM 臨床実践ガイドライン 2022
132